ProCE Banner Activity

A New Era in Prostate Cancer Treatment? Understanding DNA Repair Deficiencies and the Therapeutic Rationale for PARP Inhibition

Multimedia
In this on-demand Webcast of a CCO symposium at ASCO GU 2018, Johann Sebastian de Bono, MB, ChB, FRCP, MSc, PhD; Emmanuel S. Antonarakis, MBBCh, and Heather H. Cheng, MD, PhD, review and discuss the latest data on DNA repair defects, genetic testing, and the use of PARP inhibitors in men with prostate cancer.

Released: March 06, 2018

Expiration: March 05, 2019

No longer available for credit.

Share

Faculty

Emmanuel S. Antonarakis

Emmanuel S. Antonarakis, MBBCh

Professor
Department of Oncology and Urology
Johns Hopkins University
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland

Heather H. Cheng

Heather H. Cheng, MD, PhD

Associate Professor
Department of Medicine (Hematology and Oncology)
University of Washington
Division of Clinical Research
Fred Hutchinson Cancer Center
Seattle, Washington

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by an educational grant from

AstraZeneca

Learning Objectives

  • Describe the rationale and process for assessing germline and somatic DNA repair pathway alterations in prostate cancer
  • Examine the mechanism of PARP inhibition to achieve “synthetic lethality” in prostate cancer with deficient BRCA1/2
  • Evaluate the available clinical evidence for the use of PARP inhibitors to treat metastatic CRPC harboring BRCA1/2 or ATM mutations
  • Identify patients suitable for enrollment on ongoing clinical studies investigating PARP inhibitor monotherapy or in combination with other agents or therapies in prostate cancer

Faculty Disclosure

Primary Author

Emmanuel S. Antonarakis, MBBCh

Professor
Department of Oncology and Urology
Johns Hopkins University
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland

Emmanuel S. Antonarakis, MBBCh, has disclosed that he has received consulting fees and funds for research support from AstraZeneca and Clovis and royalties and intellectual property rights from Qiagen.

Heather H. Cheng, MD, PhD

Associate Professor
Department of Medicine (Hematology and Oncology)
University of Washington
Division of Clinical Research
Fred Hutchinson Cancer Center
Seattle, Washington

Heather H. Cheng, MD, PhD, has disclosed that she has received funds for research support from Astellas, Clovis, Inovio, Janssen, and Sanofi-Aventis.

Staff Disclosure

Staff

Rachael M. Andrie, PhD

Clinical Editor

Rachael M. Andrie, PhD, has no real or apparent conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no real or apparent conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no real or apparent conflicts of interest to report.